Your browser doesn't support javascript.
loading
Preclinical report on allogeneic uterus transplantation in non-human primates.
Johannesson, L; Enskog, A; Mölne, J; Diaz-Garcia, C; Hanafy, A; Dahm-Kähler, P; Tekin, A; Tryphonopoulos, P; Morales, P; Rivas, K; Ruiz, P; Tzakis, A; Olausson, M; Brännström, M.
Afiliación
  • Johannesson L; Department of Obstetrics and Gynecology, Sahlgrenska Academy, Sahlgrenska University Hospital, University of Gothenburg, 413 45 Göteborg, Sweden. liza.johannesson@vgregion.se
Hum Reprod ; 28(1): 189-98, 2013 Jan.
Article en En | MEDLINE | ID: mdl-23108346
STUDY QUESTION: Is it possible to perform allogeneic uterus transplantation (UTx) with a donation from a live donor in a non-human primate species and what immunosuppression is needed to prevent rejection? SUMMARY ANSWER: Allogeneic UTx in the baboon is a donor- and recipient-safe surgical procedure; immunosuppression with induction therapy and a triple protocol should be used. WHAT IS KNOWN ALREADY: UTx may become a treatment for absolute uterine factor infertility. Autologous UTx models have been developed in non-human primates with reports on long-term survival of the uterine grafts. STUDY DESIGN, SIZEAND DURATION: This experimental study included 18 female baboons as uterus donors and 18 female baboons as uterus recipients. The follow-up time was 5-8 weeks. PARTICIPANTS/MATERIALS, SETTING AND METHODS: Uterus retrieval was performed with extended hysterectomy including bilateral uterine and internal iliac arteries and ovarian veins. After UTx, with vascular anastomoses unilateral to the internal iliac artery and the external iliac vein, the uterus recipients received one of the following: no immunosuppression (n = 4); monotherapy (oral slow release tacrolimus) (n = 4) or induction therapy (antithymocyte globulin) followed by triple therapy (tacrolimus, mycophenolate, corticosteroids; n = 10). Surgical parameters, survival, immunosuppression and rejection patterns were evaluated. MAIN RESULTS AND THE ROLE OF CHANCE: The durations of uterus retrieval and recipient surgery were around 3 and 3.5 h, respectively. The total ischemic time was around 3 h. All the recipients and the donors survived the surgery. All the recipients presented rejection to some extent within the first weeks following UTx. In one recipient, the uterus was of normal appearance at the end of the study period. In spite of occasional high (>60 ng/ml) blood levels of tacrolimus, there was no evidence of nephrotoxicity. LIMITATIONS AND REASONS FOR CAUTION: This initial non-human primate allogeneic UTx study indicates that further research is needed to optimize immunosuppression protocols in order to avoid uterine rejection. WIDER IMPLICATIONS OF THE FINDINGS: The findings suggest that allogeneic UTx in primate species is feasible but continued work on this issue is needed. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by the Swedish Research Council, ALF University of Gothenburg, Hjalmar Svensson Foundation and by Jane and Dan Olsson Research Foundation. The authors do not have any competing interest.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Uterinas / Útero / Terapia de Inmunosupresión / Modelos Animales de Enfermedad / Quimioterapia de Inducción / Infertilidad Femenina Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies Límite: Animals Idioma: En Revista: Hum Reprod Asunto de la revista: MEDICINA REPRODUTIVA Año: 2013 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Uterinas / Útero / Terapia de Inmunosupresión / Modelos Animales de Enfermedad / Quimioterapia de Inducción / Infertilidad Femenina Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies Límite: Animals Idioma: En Revista: Hum Reprod Asunto de la revista: MEDICINA REPRODUTIVA Año: 2013 Tipo del documento: Article País de afiliación: Suecia